Preliminary report

Intracranial cholinergic drug infusion in patients with Alzheimer's disease

Robert Harbaugh, D. W. Roberts, D. W. Coombs, R. L. Saunders, T. M. Reeder

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

After toxicity studies in dogs, a preliminary feasibility trial of the continuous intracranial infusion of a muscarinic agonist was begun in four patients with biopsy-documented Alzheimer's disease. During the last 8 months, a totally implantable infusion system has been used to deliver bethanechol chloride into the cerebrospinal fluid of these patients at doses of 0.05 to 0.7 mg/day. Complications have been few and resolved spontaneously or were easily reversible. The subjective response to this treatment has been encouraging, with reports of improved cognitive and social function during drug infusion and a return to base line function with single-blind saline placebo infusions. Obviously, further evaluation will be necessary to demonstrate the efficacy of this treatment, and a double-blind placebo-controlled crossover trial is now being done. However, we think the preliminary results are encouraging and warrant the consideration of this approach as a potential treatment in patients with Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)514-518
Number of pages5
JournalNeurosurgery
Volume15
Issue number4
DOIs
StatePublished - Jan 1 1984

Fingerprint

Cholinergic Agents
Alzheimer Disease
Placebos
Bethanechol
Muscarinic Agonists
Cross-Over Studies
Cognition
Cerebrospinal Fluid
Dogs
Biopsy
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Harbaugh, Robert ; Roberts, D. W. ; Coombs, D. W. ; Saunders, R. L. ; Reeder, T. M. / Preliminary report : Intracranial cholinergic drug infusion in patients with Alzheimer's disease. In: Neurosurgery. 1984 ; Vol. 15, No. 4. pp. 514-518.
@article{6600f4a3a1a44ad4b162a8c04c4342f2,
title = "Preliminary report: Intracranial cholinergic drug infusion in patients with Alzheimer's disease",
abstract = "After toxicity studies in dogs, a preliminary feasibility trial of the continuous intracranial infusion of a muscarinic agonist was begun in four patients with biopsy-documented Alzheimer's disease. During the last 8 months, a totally implantable infusion system has been used to deliver bethanechol chloride into the cerebrospinal fluid of these patients at doses of 0.05 to 0.7 mg/day. Complications have been few and resolved spontaneously or were easily reversible. The subjective response to this treatment has been encouraging, with reports of improved cognitive and social function during drug infusion and a return to base line function with single-blind saline placebo infusions. Obviously, further evaluation will be necessary to demonstrate the efficacy of this treatment, and a double-blind placebo-controlled crossover trial is now being done. However, we think the preliminary results are encouraging and warrant the consideration of this approach as a potential treatment in patients with Alzheimer's disease.",
author = "Robert Harbaugh and Roberts, {D. W.} and Coombs, {D. W.} and Saunders, {R. L.} and Reeder, {T. M.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1227/00006123-198410000-00007",
language = "English (US)",
volume = "15",
pages = "514--518",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Preliminary report : Intracranial cholinergic drug infusion in patients with Alzheimer's disease. / Harbaugh, Robert; Roberts, D. W.; Coombs, D. W.; Saunders, R. L.; Reeder, T. M.

In: Neurosurgery, Vol. 15, No. 4, 01.01.1984, p. 514-518.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preliminary report

T2 - Intracranial cholinergic drug infusion in patients with Alzheimer's disease

AU - Harbaugh, Robert

AU - Roberts, D. W.

AU - Coombs, D. W.

AU - Saunders, R. L.

AU - Reeder, T. M.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - After toxicity studies in dogs, a preliminary feasibility trial of the continuous intracranial infusion of a muscarinic agonist was begun in four patients with biopsy-documented Alzheimer's disease. During the last 8 months, a totally implantable infusion system has been used to deliver bethanechol chloride into the cerebrospinal fluid of these patients at doses of 0.05 to 0.7 mg/day. Complications have been few and resolved spontaneously or were easily reversible. The subjective response to this treatment has been encouraging, with reports of improved cognitive and social function during drug infusion and a return to base line function with single-blind saline placebo infusions. Obviously, further evaluation will be necessary to demonstrate the efficacy of this treatment, and a double-blind placebo-controlled crossover trial is now being done. However, we think the preliminary results are encouraging and warrant the consideration of this approach as a potential treatment in patients with Alzheimer's disease.

AB - After toxicity studies in dogs, a preliminary feasibility trial of the continuous intracranial infusion of a muscarinic agonist was begun in four patients with biopsy-documented Alzheimer's disease. During the last 8 months, a totally implantable infusion system has been used to deliver bethanechol chloride into the cerebrospinal fluid of these patients at doses of 0.05 to 0.7 mg/day. Complications have been few and resolved spontaneously or were easily reversible. The subjective response to this treatment has been encouraging, with reports of improved cognitive and social function during drug infusion and a return to base line function with single-blind saline placebo infusions. Obviously, further evaluation will be necessary to demonstrate the efficacy of this treatment, and a double-blind placebo-controlled crossover trial is now being done. However, we think the preliminary results are encouraging and warrant the consideration of this approach as a potential treatment in patients with Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0021149967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021149967&partnerID=8YFLogxK

U2 - 10.1227/00006123-198410000-00007

DO - 10.1227/00006123-198410000-00007

M3 - Article

VL - 15

SP - 514

EP - 518

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -